Trump Administration Boosts FDA Funding for Plant-Based Infant Formula Innovation

The President's Budget has signaled a robust commitment to infant formula innovation by requesting significant funding increases for the U.S. Food and Drug Administration (FDA). This fiscal move builds upon FY26 Congressional directives aimed at modernizing regulatory guidance for plant-based, non-soy, and non-dairy formulas. These actions are expected to lower regulatory hurdles for non-traditional products entering the U.S. market. Else Nutrition has commended the administration's stance, viewing it as a major positive catalyst for its next-generation product pipeline. This development reflects a strategic shift toward diversifying infant nutrition sources and strengthening supply chain resilience through plant-based alternatives.